Literature DB >> 11263445

CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia.

Z Matrai, K Lin, M Dennis, P Sherrington, M Zuzel, A R Pettitt, J C Cawley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11263445     DOI： 10.1182/blood.v97.6.1902

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders.

Authors:  E Matutes
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

Review 2.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 3.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Authors:  Emanuela M Ghia; Sonia Jain; George F Widhopf; Laura Z Rassenti; Michael J Keating; William G Wierda; John G Gribben; Jennifer R Brown; Kanti R Rai; John C Byrd; Neil E Kay; Andrew W Greaves; Thomas J Kipps
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

5.  Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia.

Authors:  Petra Korać; Radmila Ajduković; Mirjana Mariana Kardum Paro; Branimir Jaksić; Mara Dominis
Journal:  J Mol Histol       Date:  2009-03-07       Impact factor: 2.611

6.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

Review 7.  Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Authors:  Paula Cramer; Michael Hallek
Journal:  Nat Rev Clin Oncol       Date:  2010-10-19       Impact factor: 66.675

Review 8.  Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.

Authors:  Nitin Jain; Nicole Lamanna
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

9.  Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.

Authors:  David J Allsup; James M Allan; Wei-Yu Lin; Sarah E Fordham; Nicola Sunter; Claire Elstob; Thahira Rahman; Elaine Willmore; Colin Shepherd; Gordon Strathdee; Tryfonia Mainou-Fowler; Rachel Piddock; Hannah Mearns; Timothy Barrow; Richard S Houlston; Helen Marr; Jonathan Wallis; Geoffrey Summerfield; Scott Marshall; Andrew Pettitt; Christopher Pepper; Christopher Fegan; Francesco Forconi; Martin J S Dyer; Sandrine Jayne; April Sellors; Anna Schuh; Pauline Robbe; David Oscier; James Bailey; Syed Rais; Alison Bentley; Lynn Cawkwell; Paul Evans; Peter Hillmen; Guy Pratt
Journal:  Nat Commun       Date:  2021-01-28       Impact factor: 14.919

10.  Prognostic significance of serum free light chains in chronic lymphocytic leukemia.

Authors:  Katerina Sarris; Dimitrios Maltezas; Efstathios Koulieris; Vassiliki Bartzis; Tatiana Tzenou; Sotirios Sachanas; Eftychia Nikolaou; Anna Efthymiou; Katerina Bitsani; Maria Dimou; Theodoros P Vassilakopoulos; Marina Siakantaris; Maria K Angelopoulou; Flora Kontopidou; Panagiotis Tsaftaridis; Nikolitsa Kafasi; Gerasimos A Pangalis; Panayiotis P Panayiotidis; Stephen Harding; Marie-Christine Kyrtsonis
Journal:  Adv Hematol       Date:  2013-10-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.